

Mechano-Cas12a Assisted Tension Sensor (MCATS) for Massively Amplified Cell Traction Force Measurements

Yuxin Duan¹, Fania Szlam², Yuesong Hu¹, Wenchun Chen³, Renhao Li³, Yonggang Ke⁴, Roman Sniecinski^{2*}, Khalid Salaita^{1*}

¹Department of Chemistry, Emory University, Atlanta, Georgia, 30322, USA.

²Department of Anesthesiology, School of Medicine, Emory University, Atlanta, Georgia, 30322, United States

³Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Departments of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, 30322, USA.

⁴Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, 30322, USA.

*Correspondence should be addressed to k.salaita@emory.edu; rsnieci@emory.edu

Abstract

Cells transmit piconewton forces to mediate essential biological processes such as coagulation. One challenge is that cell-generated forces are infrequent, transient, and difficult to detect. Here, we report the development of Mechano-Cas12a Assisted Tension Sensor (MCATS) that utilizes CRISPR-Cas12a to transduce and amplify the cumulative number of molecular force events generated by cells. We demonstrate the power of MCATS by detecting the forces generated by as few as $\sim 10^3$ human platelets in a high-throughput manner. Platelet forces are significantly inhibited when blood samples are treated with FDA-approved drugs such as aspirin, eptifibatide (Integrilin®), 7E3 (Reopro®), and ticagrelor (Brelinta®). Because MCATS requires $< 5 \mu\text{L}$ of blood/measurement, a single blood draw can generate a personalized dose-response curve and IC_{50} for this panel of drugs. Platelet activity and force-generation are tightly associated, and hence MCATS was used to quantify platelet dysfunction following cardiopulmonary bypass (CPB) in a pilot study of 7 cardiac patients. We found that MCATS detected platelet dysfunction which strongly correlated with the need for platelet transfusion to limit bleeding. These results indicate MCATS may be a useful assay for clinical applications.

The ability for cells to generate mechanical forces is central to a wide range of biological processes ranging from immunology to coagulation and plays an important role in numerous pathologies such as cancer.¹⁻⁴ Therefore, developing methods to quantify cell-generated force has important biomedical applications. A central challenge in this field is that molecular forces that are sensed and transduced by cells are fairly weak, at the scale of piconewtons (pN)⁵ and are highly transient and infrequent⁶. Our lab and others recently developed DNA-based tension sensors that respond to cell generated pN forces and can be imaged using high-power microscopes with single molecule sensitivity.⁷ Despite the advances in mechanobiology enabled by DNA tension sensors,^{3, 5, 7-9} the use of these probes remains limited because of the weak signal and need for dedicated microscopy instrumentation. To facilitate the study of mechanobiology, it is important to develop facile, robust, and sensitive assays that can be broadly adopted by the community.

In biochemistry and molecular biology, weak or difficult to detect signal is typically enhanced by using catalytic amplification reactions such as PCR and ELISA. However, these assays have poor compatibility with live cell measurements. For example, thermal cycling in PCR would destroy most cells. An emerging class of enzymatically amplified reactions that are used in molecular diagnostics are based on clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas).^{10, 11} One notable Cas enzyme used in diagnostics is CRISPR-Cas12a (Cpf1) which is a class 2 type V-A enzyme that is loaded with single-stranded guide RNA (gRNA) and is activated upon binding to a complementary single stranded activator DNA. Upon activation of Cas12a, the enzyme undergoes a conformation change that unleashes its indiscriminate cleavage activity (trans activity) which hydrolyzes any ssDNA in proximity.¹² The nuclease activity of Cas12a is robust, highly efficient with $k_{cat}/K_m \sim 10^6\text{-}10^7 \text{ M}^{-1}\text{s}^{-1}$, and thus has been used for a number of diagnostic assays for nucleic acid sensing¹³ such as DETECTR¹⁴ and for metal ion detection^{14, 15}. Given the sensitivity and specificity of Cas12a based assays, we were inspired to adopt Cas12a enzyme to address the limited signal in cellular tension sensing assays.

Specifically, we developed a Mechano-Cas12a Assisted Tension Sensor (MCATS), which is an ultrasensitive fluorescence-based assay to detect the aggregate number of molecular force events. In MCATS, the activator is a ssDNA anchored to a surface, such as a glass slide. The activator is concealed by hybridization to a complementary strand that is in turn conjugated to a peptide such as, cyclo-Arg-Gly-Asp-Phe-Lys (cRGDfK), or any protein ligand specific to the cell receptor of interest (**Figure 1a-b**). When cells are seeded on this surface, surface receptors such as integrins bind to the cRGDfK ligand on the duplex and apply forces. Forces that exceed the mechanical tolerance of the duplex lead to its rupture, exposing the activator (bottom strand) and thus triggering Cas12a nuclease activity. Upon activation, Cas12a will indiscriminately and catalytically cleave fluorogenic single stranded DNA reporter for amplification. Because Cas12a is highly efficient, its activation generates a massive fluorescence signal output that can be measured using a conventional fluorometer or plate reader for facile and high throughput readout.

MCATS is a platform technology and can be applied to study many different types of cells and different biological processes. As a proof-of-concept demonstration, we used MCATS to investigate the forces generated by human platelets because of the importance of mechanical forces in platelet function. Indeed, recent studies using micropatterned polymer structures showed that platelets forces can be used to detect underlying genetic clotting disorders¹⁶, and for predicting trauma-induced coagulopathy.¹⁷ Because MCATS only requires ~5 uL of blood or less to conduct each measurement, a typical blood draw (~5 mL) allows one to run ~1000 assays in a rapid manner. We leveraged this capability to screen the activity of a panel of clinically approved anti-platelet drugs such as aspirin, integrilin, abciximab, and Brelinta. These experiments demonstrate the potential of MCATS for personalized tailoring of anti-coagulant drugs and may help guide therapeutic intervention in the clinic.¹⁸ We also applied MCATS to detect platelet dysfunction following cardiopulmonary bypass (CPB). In a pilot study of seven CPB patients, we found that the change in MCATS signal strongly correlated with the need for platelet transfusion. More broadly, MCATS offers an accurate, rapid, and cost-efficient method to detect the integrated number of molecular force events generated by cells and will hence open the door to integrating mechanical measurements into the clinic.

Results

Design and optimization of MCATS

We first designed a double stranded DNA tension probe that can be mechanically ruptured by cell generated forces to expose the immobilized activator. The trans activity of gRNA-Cas12a nuclease can be activated using two different routes (**Figure 1a**).¹² The first involves a dsDNA that incorporates the PAM sequences. Only dsDNA that is complementary to the gRNA and that incorporates the 4 nt PAM sequence can activate the nuclease. The second route involves a ssDNA sequence that is complementary to the gRNA. The PAM sequence is not required in this case. For MCATS, we designed a PAM-free dsDNA probe and thus this sequence is unable to activate Cas12a. However, upon mechanical denaturation of this duplex, the bottom strand is exposed, thus revealing a 20 nt ssDNA domain complementary to the gRNA. Thus, the gRNA/Cas12a complex is exclusively activated as a result of cell-generated forces transmitted to the immobile probe. Active Cas12a, then catalytically cleaves fluorogenic single strand reporter DNA (**Figure 1b-1c**). The reporter DNA was comprised of a short poly T sequence to minimize secondary structure and was tagged with a quencher-fluorophore pair at its termini, such that it was dequenched upon Cas12a hydrolysis. The activator domain is not restricted to the sequence used here and can be designed to tune the force response being detected. The sequences of all oligonucleotides used in this work are provided in **Table S1**.

Given that surface-tethered Cas12a had not been reported in the literature, and the potential for hindered activity due to immobilization¹⁹, we first measured the kinetics of Cas12a when the activator is immobilized on a surface and compared it to reactions where the activator was in solution. In this assay, biotinylated activator (100 nM) was anchored to streptavidin-coated surfaces by incubating for 1 hr at RT. Based on our previous surface calibration, this procedure generates a DNA density of 1330 ± 60 molecules/ μm^2 .²⁰ Next, the gRNA-Cas12a complex (20 nM) and reporter DNA (100 nM) were added to the surface and a fluorescence plate reader was used to monitor the fluorescence signal in each well of the 96 well plate. The measurement showed that ss-activator triggered the Cas12a nuclease and generated a strong fluorescent response. In contrast, the ds-activator (concealed activator) only showed minimal signal (**Figure 1d**).

Next, we tested whether adding a spacer to the activator may boost Cas12a cleavage rates. We tested four activators with different length polyT spacers of 0, 6, 60, and 160 nt. The surface density calibration showed that 6 and 60 polyT spacers only reduced surface density slightly (~18%) while the long 160nt spacer caused the surface density to decrease to 60% of the 0-nt spacer probe (**Extended data figure 1**). The apparent initial rate constant (fluorescence signal change between $t = 10$ and 20 min) for these immobilized activators is plotted in **Figure 1e** and showed that the apparent initial rate constant was enhanced with longer spacers with the exception for the 160 nt activator. The enhanced activity with longer spacers is likely due to reduced steric hinderance, but this effect is offset by the reduced effective activator density at extreme spacer lengths. Notably, we expect that the Cas12a will release the activator from the surface with suitable length spacers. This is supported by the observation that activator surface density is diminished by 70% for the 60 polyT spacer after 1 hr of adding the Cas12a (**Extended data figure 2**). All subsequent work with MCATS employed the activator with 60T spacer due to its superior signal amplification.

To further optimize MCATS, we measured Cas12a activity as a function of assay temperature, buffer, and reaction time (**Figure S1**). The results indicate the Cas12a work best at 37 °C, in cell culture medium with 10mM of Mg^{2+} . We also compared the signal to noise ratio (S/N) of the assay using two reporter oligonucleotides (**Figure S2**). The reporter strand tagged with Atto565N-BHQ2 shows a ~two times higher S/N compared with FAM-Lowa black reporter strand because of its better quenching efficiency. Using the optimized conditions, we investigated the limit of detection (LOD) of our assay both for surface tethered activator as well as soluble activator as a reference (**Figure 1f-g**). To tune the activator surface density, we created surfaces comprised of a binary mixture of single stranded DNA activator and the blocked (double stranded) control DNA. We maintained a total activator solution concentration of 100 nM but tuned the ratio between the blocked DNA and single stranded activator. We then added Cas12a-gRNA and fluorogenic reporter to the well and measured the final fluorescence intensity after 1hr of enzyme activity. The LOD was then inferred from the ratio of 3.3 x standard deviation of the background normalized by the slope of the

fluorescence versus concentration plot. The results showed that the LOD for nucleic acid sensing was 95.2 fM in solution and 1712 molecule/mm² on a surface. This analysis provides the basis for using MCATS to sensitively detect the cumulative number of molecular force events generated by cells.




Figure 1. Scheme and characterization of MCATS. a) Schematic showing the potential mechanisms of activating Cas12a. b-c) Flow chart and scheme depicting MCATS. Molecular traction forces mechanically melt the duplex probe and reveal an activator sequence that triggers Cas12a to cleave reporter strands in solution. The activator was tagged with Atto647N to aid in quantification and validation. d) Characterization of Cas12a activity for surface-tethered activators of 0, 6, 60, and 160 polyT linkers along with negative controls using concealed (duplexed) activators. Plot of time-dependent fluorescence intensity measured using a conventional plate reader. Error bars represent S.E.M. obtained from three independent experiments. e) Plot of Cas12a apparent initial cleavage rate as a function of linker length for immobilized activator. The apparent rate was determined using the change in fluorescence between $t = 10$ min and 20

min. The error bars stand for S.E.M of n=3 independent experiments. f) Plot of fluorescence intensity at $t = 1$ hr as a function of activator concentration for reactions employing 20 nM Cas12a-gRNA complex and 100 nM reporter DNA. Each reaction also contained 100 nM of dsDNA to mimic the concealed activator. Data points represents average MCATS measurement of 3 independent experiments. The error bars stand for S.E.M of n=3 independent experiments. LOD = $3.3(\text{standard deviation of blank/slope of calibration curve}) = 95.2 \text{ fM}$. g) Plot of fluorescence intensity as a function of surface density of activator. Each reaction contained 20 nM Cas12a-gRNA complex and 100 nM reporter DNA. Surface displayed a binary mixture of activator and scrambled DNA. LOD = $1712 \text{ molecule/mm}^2$. The error bars stand for S.E.M of n=3 independent experiments.

Rapid, robust, ultrasensitive detection of tension with MCATS

We next applied the MCATS assay to detect integrin-mediated cell traction forces in immortalized cell lines. Integrins are a family of heterodimeric cell surface adhesion receptors that bridge the cellular cytoskeleton with the extracellular matrix (ECM) to mediate a variety of processes including cell adhesion, and migration.² Previous research has shown that integrin receptors can apply pN forces which are sufficient to mechanically denature DNA duplexes.²¹ Hence, measuring integrin receptor forces with NIH/3T3 cells is an appropriate model to validate the MCATS assay.

As is shown in **Figure 2a**, DNA duplexes that present cRGDfK ligand and concealed Cas12a activator were immobilized on the surface. The conjugation of ligand to duplex was achieved via copper(I)-catalyzed azide-alkyne cycloaddition and was verified with ESI-MS (**Figure S3**, **Table S2**). NIH/3T3 fibroblast cells were then seeded on these surfaces for 1 hr.


We designed two types of DNA duplexes that have identical sequence and thermal melting temperatures, but different geometries and mechanical tolerances (**Figure 2b**). When the activator is anchored through its 5' terminus, the cRGDfK ligand is presented on the 3' terminus of the top strand. Hence this probe denatures through an unzipping process which has a lower activation barrier and displays a mechanical rupture threshold of 12 pN. In contrast, when the activator is anchored through its 3' terminus, the probe denatures by shearing which has a larger mechanical threshold of 56 pN.

The same number of cells (25,000 cells) were incubated on the two types of surfaces for 1 hr before running the Cas12a amplification assay. As expected, we observed an increase in fluorescence signal for both the 12 pN and 56 pN probes (tagged with fluorophore quencher pairs) due to mechanical denaturation of the duplex (**Figure 2c**). As expected, the probes in the unzipping geometry (12 pN) were more significantly denatured compared to shearing mode probes (56 pN), in agreement with past literature (**Figure 2b-c**).²² We next added the Cas12a and reporter DNA to trigger the MCATS assay for 1 hr and then measured bulk fluorescence ($\lambda_{\text{ex}} = 540 \text{ nm}$ and $\lambda_{\text{em}} = 590 \text{ nm}$) using the plate reader (**Figure 2d**). Importantly, the 12 pN unzipping mode probes also generated a greater MCATS signal, reflecting the greater density of exposed activator. MCATS produced over 100-fold greater signal compared to mechano-HCR which confirms that this assay is more sensitive and offers a simplified experimental process as no washing steps are required (**Figure S4**).²⁰

We further validated the MCATS assay by seeding increasing numbers of NIH/3T3 cells in 96 well plates and measuring associated MCATS signal in each well. We observed that increasing cell densities led to greater MCATS signal (**Figure 2e-f**). Impressively, we found that MCATS can detect the tension generated from as few as 50 fibroblasts in a 96 well plate using a conventional plate reader (**Figure 2e inset**). We further tested whether MCATS can be used to produce a dose response curve for NIH-3T3 cell incubated with Rho kinase inhibitor, Y-27632, which targets the phosphorylation of myosin light chain and therefore dampens forces transmitted by focal adhesions. We pretreated NIH/3T3 cells with a range of Y-27632 concentrations (0-50 μM) for 30 min and then ran MCATS with the drug treated cell. MCATS signal showed a dose-dependent reduction as a function of increasing Y-27632 concentration (**Figure 2g-h**), indicating that plate-reader based MCATS readout can report cell forces modulated by MLC inhibition. By fitting the data to a standard dose-response inhibition function ($\text{signal} = 100/(1 + [\text{drug}]/\text{IC}_{50})$), we found that the mechano- $\text{IC}_{50} = 7.9 \mu\text{M}$ (95% CI = $5.5 - 11.6 \mu\text{M}$), which matches previous literature reporting IC_{50} of $5 - 10 \mu\text{M}$.²³

202
203
204
205
206
207
208
209
210
211
212
213
214
215

Given that integrin display is highly heterogeneous across cell types and tissues, we next applied MCATS to measure integrin-subtype mediated forces in HeLa cells, which express $\alpha_5\beta_1$, $\alpha_v\beta_5$, and $\alpha_v\beta_3$ integrins.²⁴⁻²⁶ Moreover, integrin $\alpha_v\beta_3$ levels are correlated with the malignancy potential of tumor cells.²⁷ To study how specific integrin subtypes mediate differential traction forces, we incubated cells with two different types of monoclonal antibodies: anti- $\alpha_5\beta_1$ and anti- $\alpha_v\beta_3$ for 30min at 10 μ g/ml prior to running the MCATS assay. The results showed that inhibition of integrin $\alpha_5\beta_1$, and $\alpha_v\beta_3$ led to a significant decrease in MCATS signal on 12pN probes (**Extended data figure 3**, $P=0.003$ for blocked $\alpha_v\beta_3$ and $P=0.01$ for blocked $\alpha_5\beta_1$). However, on 56pN probes, only inhibition of $\alpha_5\beta_1$ showed a significant decrease in MCATS signal ($P=0.04$). The result confirms that $\alpha_5\beta_1$ and $\alpha_v\beta_3$ both contribute to adhesion and traction force generation of HeLa cells. However, $\alpha_5\beta_1$ primarily exerts $F > 56$ pN, which is consistent with precedent literature indicating greater rupture forces for $\alpha_5\beta_1$ than that of $\alpha_v\beta_3$.^{28, 29} These results further validate the versatility of using MCATS for screening integrin-specific force transmission which may have implications in mechanotyping cancer cell lines.



216
217
218
219

Figure 2. MCATS demonstration using fibroblasts. a) Schematic of MCATS assay to study NIH/3T3 integrin-mediated forces. b) Schematic comparing designs of concealed activator in shearing and unzipping geometries. c) Representative RISM and fluorescence images of cells cultured on unzipping (12 pN) and

shearing (56 pN) surfaces at $t = 0$, and 1hr after cell seeding. Scale bar = 12 μm . The fluorescence emission is due to dequenching of Atto647N following top strand denaturation. The intensity bar indicates the absolute range of intensity values for each image. d) Plot shows MCATS signal measured using plate reader for cells incubated on $T_{\text{tot}} = 12$ pN and $T_{\text{tot}} = 56$ pN surfaces. Error bars represent S.E.M. from $n=3$ independent experiments. e) Plot showing plate reader measured MCATS signal as a function of the number of cells seeded. Error bar represents S.E.M. from four independent experiments. Inset shows signal in the regime of low numbers of cells (50-5000 cells). f) Representative RISM and duplex rupture (red) fluorescence images for unzipping probes. Scale bar = 12 μm . g) Plot of MCATS signal as a function of Y-27632 concentration. Drug was incubated for 30 min prior to seeding cells on the surface. Error bar represents S.E.M. from 3 independent experiments. Mechano-IC₅₀ was calculated by fitting plot to a standard dose-response function: normalized signal = $100/(1+[drug]/IC_{50})$. The values were normalized to the signal obtained from the 25,000 cells/well samples without drug treatment. All measurements were background subtracted using negative control wells lacking cells. h) Representative RISM and duplex rupture (red) fluorescence images of drug-treated fibroblasts at $t = 1$ hr after seeding. Scale bar = 12 μm .

Measurement of platelet traction forces using MCATS

Platelets are primary cells and are well suited for MCATS analysis because contractile forces are critical in platelet function in forming clots that mechanically resist blood shear flow and seal a wound. Thus, we tested if MCATS can be used to measure platelet traction forces in a high throughput manner (**Figure 3a**). We first purified human platelets from blood samples collected in collection tubes containing sodium citrate or EDTA from donors. The sample was then centrifuged for 12 min at 140 g (with 0.02U Apyrase) to obtain platelet-rich plasma (PRP). Then platelets were prepared from PRP by centrifugation for 5 min at 700 g with 3 μM PGE-1. The platelets were then resuspended in Tyrodes buffer and centrifuged for 5 min at 700 g with 3 μM PGE-1. Finally, platelets were resuspended in Tyrodes buffer. It is worth noting that Apyrase is important in the platelet purification process to prevent hemolysis mediated platelet aggregation (**Figure S5**). In additional controls, we found that tubes containing either EDTA or citrate will not influence platelet tension after purification (**Figure S5**).

We first tested MCATS as a function of the number of platelets seeded on the unzipping duplex surfaces. We found that MCATS detected tension signal from as few as 2000 platelets (**Extended data fig 4**). We chose 2×10^6 platelets in the following experiments because this concentration of platelets in a 96-well plate offered the strongest signal for the assay. To validate that MCATS response was sensitive to the mechanical tolerance of the probes, we tested platelets that were seeded on DNA tension probes in shearing and unzipping geometries, with thresholds of 56 and 12 pN, respectively. MCATS signal was six-fold greater on the unzipping probes compared to that of the shearing duplex probes which is consistent with literature precedent by our group and others (**Figure 3b-c**).^{2, 20, 30-32} To better characterize the reproducibility of MCATS, we performed 10 measurements on platelets collected from a single healthy donor. As is shown in **Figure 3d**, the mean of the measurements was 125,000 $\pm$ 14,700 a.u., showing a coefficient of variation of 11.7%. Interestingly, this value is comparable to the CV reported for other FDA-approved coagulation assays such as Multiplate ($\sim 14.4\%$)³³, VerifyNow ($\sim 17.7\%$)³³, and light transmission aggregometry (LTA) ($\sim 5-12\%$)³⁴. Furthermore, we also estimated the day-to-day variance in MCATS signal for two healthy donors (**Extended data fig 5**). The coefficient variation for the two donors from three independent blood draws were 0.09 and 0.16, which is consistent with the assay variance, indicating that healthy platelet may maintain stable tension levels for many months. However, due to the limited number of donors studied over a fairly short time window, further investigation is needed to better quantify time-dependent changes in platelet mechanical contractility. Taken together, these experiments help reveal MCATS signal variation when testing the same pool of platelets from a single blood draw as well as the variation across multiple blood draws.

Another parameter that could influence platelet traction forces is ADP agonist concentration which is well known to trigger platelet activation and adhesion. We therefore tested the dose-response of platelets to agonist using MCATS and found increasing tension signal as a function of ADP. These results were further validated with LTA which is commonly used to assess platelet function (**Figure 3e**, **Extended data fig 6**).

Aggregometry, however, requires 100-fold greater sample volumes and dedicated instruments which shows the advantage of MCATS in assessing platelet function with cellular forces. Other agonists such as TRAP and collagen were also tested and showed increasing tension signal as a function of dose of agonist (Figure S6).




Figure 3. MCATS for high-throughput measurement of platelet traction force a) Schematic showing mechanism of MCATS to quantify platelet-mediated forces. b) Bar graph shows MCATS signal of the same number of platelets incubated on T_{tol}= 12 pN and T_{tol}= 56 pN probes. Error bars represent S.E.M. obtained n=3 blood draws from 3 donors and each was color-coded. The MCATS signal from each unique blood draw was averaged from technical replicates (different wells). c) Representative RICM and fluorescence images of cells cultured on T_{tol}= 12 pN and T_{tol}= 56 pN surfaces for 1hr. Scale bar = 12 μm. The red color is emission from Atto647N tagging the activator. The intensity bar next to each fluorescence image shows the absolute signal intensity for each image. d) MCATS reproducibility analysis. The plot shows the MCATS signal of 10 independent measurements of the same platelet sample collected from a single blood draw. The black line represents the mean and standard deviation. e) Plot of MCATS signal (purple) and primary aggregation (beige) signal obtained from donor platelets upon activating with ADP. Aggregometry data collected from a single donor. MCATS signal is the average from n=4 donors. The values were normalized to the signal obtained from the wells with 20 μM ADP. Error bar stands for standard error of the mean from n=4 donors.

High-throughput determination of platelet inhibitors' influence on platelet tension

We next investigated the MCATS signal of human platelets under the influence of different antiplatelet drugs. Anti-platelet agents are some of the most commonly prescribed drugs in the world. Currently, 30 million Americans take anti-platelet medications such as daily aspirin to reduce the risk of cardiovascular events, but ~16.6 of 100 patients experience bleeding as a side effect and 5% are resistant to aspirin.³⁵

We tested multiple types of FDA-approved antiplatelet drugs: aspirin which inhibits the activity of cyclooxygenase (COX), the integrin α_{IIb}β₃ (also known as GPIIb/IIIa) antagonists eptifibatide, 7E3 (monoclonal antibody) as well as the P2Y₁₂ inhibitor ticagrelor (Figure 4a).³⁶⁻³⁸ As is shown in Figure 4b, aspirin targets cyclooxygenases 1 and 2 (COX-1 and COX-2), leading to an inhibition of prostaglandin biosynthesis and synthesis of thromboxane A₂ (TxA₂) which is essential in platelet activation and traction force generation.³⁹ Integrilin and 7E3 are drugs that selectively bind to α_{IIb}β₃ integrins and compete with fibrinogen binding.^{40,41} Blocking the integrin receptor with either drug dampens outside-in mechanical signal transduction and decreases platelet activation and force transmission. Finally, ticagrelor is an inhibitor of the purine receptor, P2Y₁₂, which is critical in driving platelet activation following ADP binding. P2Y₁₂ is a G-

306 protein coupled receptor (GPCR) that activates PLC β and generates a Ca²⁺ flux that boosts myosin
307 contractility and traction force generation by the platelet.⁴² In the drug inhibition experiments, we incubated
308 platelets with different drugs at room temperature for 30 minutes and plated 2×10^6 treated human platelets
309 in each well for 1hr and then performed MCATS. For all the compounds tested, we observed a dose-
310 dependent decrease in the 12 pN duplex rupture in both microscopy imaging of duplex ruptures as well as
311 MCATS signal that was detected using a plate reader (**Figure 4c-f, Extended data fig 7**). All drugs showed
312 a significant drop in signal upon treating platelets. ($P < 0.0001$, 0.009, < 0.0001 , 0.005 for aspirin, Eptifibatide,
313 7E3 and Ticagrelor respectively) By fitting the plot of MCATS signal with a standard dose-response inhibition
314 function ($\text{Signal} = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + ([\text{drug}] / \text{IC}_{50}))$), we determined the mechano-IC₅₀ for aspirin,
315 eptifibatide, 7E3 and Ticagrelor for each individual donor and plotted the data in **Figure 4c-4f**. MCATS was
316 found to be robust as the signal generated from the same blood draw of the same donor was highly
317 consistent ($\sigma \sim 10\%$). However, we found donor-to-donor variability in mechano-IC₅₀ which likely reflects the
318 biological heterogeneity of the drug response especially in aspirin treated group. Importantly, the values we
319 measured were consistent with literature precedent.^{41, 43-46} Because each measurement only requires 2×10^6
320 platelets while 1ml of blood contains $\sim 10^9$ platelets, a typical 5 ml blood draw can be used to run $\sim 2,500$
321 assays thus opening the door for massive screening to determine drug sensitivity in a personalized manner.




Figure 4. MCATS for personalized antiplatelet drug-sensitivity measurement. a) Schematic showing overall MCATS workflow using human platelets. b) Mechanism of different anti-platelet drugs inhibiting platelet traction forces. c-f) Plots of MCATS signal for platelets before and after inhibition using 0.1 mM aspirin, eptifibatide (1 μ M), 7E3 (10 μ g/ml), and Ticagrelor (1 μ M). Donor platelets were treated with the inhibitor for 30 min at RT prior to performing MCATS. Each data point represents the average of $n=2$ measurements on different chips from a single donor. Different donors are color-coded. The mean and S.E.M. are shown for each drug treatment. Data was normalized to average of non-treated group. Significance is calculated with two tailed student t-tests. **, ***, **** represents p value <0.01 , 0.001 and 0.0001 . $P=<0.0001$, 0.009 , <0.0001 , 0.005 for aspirin, Eptifibatide, 7E3 and Ticagrelor respectively. The bottom set of plots show the mechano-IC₅₀ calculated from a dose-response titration of six drug

concentrations for each drug for color-coded individual donors. The MCATS signal at each drug concentration for each donor is obtained from an average of $n=2$ measurements collected from different chips. Body of the box plots represent first and third quartiles and red horizontal line represents the literature reported IC₅₀. Error bars represent S.E.M. for each drug from $n=8$ for aspirin, 4 for eptifibatide, 4 for 7e3 and 5 for ticagrelor. Mechano-IC₅₀ was calculated by fitting plot to a standard dose-response function: $\text{Signal} = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + ([\text{drug}] / \text{IC}_{50}))$.

MCATS detects platelet dysfunction and correlates with transfusion need in subjects following CPB

Finally, we investigated whether MCATS can be used to assess platelet dysfunction in cardiac patients using CPB. In a subset of patients (10-23%), CPB leads to severe postoperative bleeding requiring blood transfusion⁴⁷⁻⁴⁹. Past literature has demonstrated that CPB surgery and other extracorporeal circuits such as extracorporeal membrane oxygenation (ECMO) lead to changes in membrane glycoprotein GPIb-IX-V⁵⁰ as well as integrin activation⁵¹ which results in platelet dysfunction.⁵² The likelihood of patient bleeding following CPB is typically assessed using platelet function assays such as impedance aggregometry and thromboelastography (TEG). Despite their widespread use, such assays provide only a weak prediction of severe bleeding. For example, the PLATFORM clinical trial showed that impedance aggregometry has a 40% predictive value for severe bleeding⁵³ while other studies showed that TEG has a 0.78 area under the curve (AUC) for predicting postoperative bleeding^{54, 55}. This is likely because TEG and aggregometry are highly dependent on platelet count which can bias aggregation dynamics.⁵⁶ The ability to anticipate the risk of developing coagulopathy due to platelet dysfunction more accurately is desirable as it could aid in determining the optimal timing of cardiac surgery for patients on antiplatelet agents, as well as targeting platelet transfusions to offer blood products to the patients who need it most. Given that bleeding risk is multifactorial, developing additional assays based on different transduction mechanisms may complement current techniques and offer improved capabilities to detect platelet dysfunction and bleeding risk.

We performed MCATS on $n=6$ healthy subjects as well as $n=7$ cardiac patients pre- and post-CPB (**Figure 5a**). The demographic information and related health information for these subjects can be found in **Table S3**. All CPB patients were tested using TEG (using a TEG6S system) and aggregometry in the clinic pre- and post- surgery, and these measurements were benchmarked against MCATS. Note that due to low count platelet, one subject did not have an accompanying aggregometry measurement. The MCATS score for each donor was averaged from $n=3$ or 4 replicate measurements where 2×10^6 platelets were seeded in a well and the fluorescence intensity was measured at $t = 1$ hr after seeding. In general, healthy donors ($n=6$) showed similar MCATS tension signal which was greater than that for CPB donors prior to surgery. This is likely because many of the CPB patients had underlying health conditions, but this premise is yet to be validated. After CPB, subjects showed a significantly reduced MCATS signal (decrease of $35\% \pm 18\%$, $P=0.0002$) that ranged from 48% to 17% (**Figure 5b**). Within 24 hrs after CPB, 5 out of the 7 patients required platelet transfusion to minimize bleeding. We hypothesized that the magnitude of MCATS signal reduction (mechanical dysfunction) is an indicator of the severity of platelet dysfunction, and hence we compared the change in MCATS signal (%) to the number of units of transfused platelets (**Figure 5c**). We found that the number of transfused platelets given to the patient within 24 hrs after surgery were strongly positively correlated with the drop in platelet MCATS signal (**Figure 5c**, Pearson's $r = 0.83$, $P=0.020$). As expected, aggregometry analysis (with $10 \mu\text{M}$ of ADP) of the same samples showed a decrease of $47\% \pm 18\%$, $P=0.05$ in primary aggregation following CPB. TEG showed a decrease of $29\% \pm 14\%$, $P=0.001$ in maximum aggregation (MA) for the same cohort (**Figure 5d, 5f**). Note that one of the CPB subjects showed an increase in aggregometry value following surgery which further underscores the variability in aggregometry. When the aggregometry and TEG signal change was compared to the number of platelet units transfused, we found a weakly positive correlation for aggregometry and a strong correlation for TEG (**Figure 5e, 5g**, Pearson's $r = 0.16$, $P=0.32$ for aggregometry and Pearson's $r = 0.86$, $P=0.012$ for TEG). Our initial pilot study indicates that the mechanical forces generated by platelets offer a unique metric to quantify platelet function. The MCATS assay produces a readout that is correlated with bleeding risk and provides a comparable functional test on par with methods currently used in the operating room such as TEG. Thus, MCATS may offer a complementary indicator of post-op bleeding risk following CPB.

385

386 We also performed controls to validate MCATS measurement for subjects following CPB. Following standard
387 of care procedures, patients were treated with heparin prior to surgery to minimize blood clotting and this
388 was neutralized with protamine post operation. To confirm that the decrease in MCATS signal is not due to
389 inhibition of heparin, we performed MCATS on controlled platelets that were treated with heparin and then
390 neutralized with protamine. The results showed that heparin led to a slight decrease in MCATS signal, but
391 this inhibition was fully reversed upon protamine treatment (**Figure S7**). We also tested the mechano-IC₅₀ of
392 aspirin and Ticagrelor for the CPB donors before and after surgery. The results showed that the surgery did
393 not influence the mechano-IC₅₀ significantly (**Extended data fig 8**), which confirms that MCAT is insensitive
394 to platelet count.










Figure 5. MCATS detects platelet dysfunction for patients following CPB. a) Schematic of workflow using MCATS to assess platelets dysfunction following CPB. b) Plot of MCATS platelet signal for healthy donors ($n = 6$), pre-CPB and post-CPB subjects ($n = 7$). Error bars represent S.D. from $n = 4$ measurements for the same platelets unless a well is defaulted. Significance is calculated with two tailed student t-test with $P=0.002$. c) Plot of MCAT reduction in signal (%) against the number of platelets transfusions given to the subject within 24 hrs of CPB. Data points are color coded for each subject and represents the mean percentage loss of mechanical force in the patient platelets before and after surgery. Error bars represent S.D. of $n=3$ measurements. Pearson's correlation coefficient $r= 0.83$ with *two-tailed* $P=0.020$. d) Plot of aggregometry PA (mm) for subjects pre-CPB and post-CPB. e) Plot of aggregometry PA decrease (mm) vs platelet transfusion needs within 24 hrs of CPB. Note that one patient lacked aggregometry data because of severe hemolysis. Pearson's correlation coefficient $r= 0.16$ with *two-tailed* $P=0.32$. f) Plot of TEG MA (mm) for subjects pre-CPB and post-CPB. g) Plot of TEG MA decrease (mm) vs platelet transfusion need. Pearson's correlation coefficient $r= 0.86$ with *two-tailed* $P=0.012$.

Discussion

The current state of the art tools for measuring platelet function are based on aggregometry and viscoelastic assays (TEG)⁵⁷ which are routinely used in clinical practice. Aggregometry measures the light transmission of platelet rich plasma samples using an instrument that applies shear as well as a specific agonist such as ADP and TRAP. Aggregometry records multiple parameters including the kinetics of aggregation to infer clotting functions. Similarly, TEG records the drag forces in whole blood samples which measures the kinetics of clot formation and viscoelastic properties of clots. The limitations of these assays are multifold. First, unlike MCATS which requires a standard well plate reader that is already used for most ELISA assays, TEG and aggregometry assays require dedicated instruments. Secondly, LTA and TEG require ~mL quantities of blood for each measurement which may not seem significant for healthy adults, but may be more challenging for patients experiencing thrombocytopenia, bleeding or for neonates. Moreover, creating drug dose-response curves such as those shown in **Figure 4** from a single blood draw would be fairly challenging using LTA and TEG. Even more importantly, TEG and LTA assays have limited sensitivity given that these assays require platelet aggregation which is highly dependent on platelet count, coagulation factors such as fibrinogen level and antiplatelets agents usage.⁵⁸⁻⁶⁰ Patients with higher platelet counts will tend to form more stable aggregates regardless of the functional activity of each individual platelet⁶¹ and patient with a low platelets count due to surgery or underlying conditions have difficulty in TEG and aggregometry assays. According to the PLATFORM study, aggregometry shows limited predictive value in identifying post operative bleeding following CPB.⁵³ Indeed, in our work, we encountered one patient with a low platelet count which would present a significant challenge for TEG but this did not hamper the MCATS assay. Considering that platelet count is closely linked with coagulation, we analyzed the relationship between platelet count and the clinical platelet transfusion need. When we plot platelet count against the number of transfused platelet units we found a positive correlation that was not statistically significant ($r= 0.72$, $P=0.07$; **Figure S8**). This is consistent with the literature as platelet count is only one factor in determining bleeding risk. In patients undergoing chemotherapy, for example, platelet count by itself does not determine bleeding risk.⁶² Thus, MCATS offer an orthogonal and complementary measurement of platelet function with potential clinically relevance. We envision that MCATS will complement LTA and TEG both of which are highly platelet count dependent.^{63, 64}

We found that the decreased platelet tension in CPB patients is correlated with need for platelet transfusion to minimize bleeding. Further underscoring the importance of platelet force in bleeding, Greulich and colleagues demonstrated that peak platelet force after CPB was significantly lower, which is likely to play a role in CPB-associated microvascular hemorrhage.⁶⁵ However, the process of coagulation involves a complex cascade and diverse factors in CPB contribute to coagulopathy. The factors include physical factors (shear flow and hypothermia), exposure to artificial material, drugs administration, and the release of endogenous chemicals. Due to this complexity, the mechanism behind the observed correlation between bleeding and mechanical forces in CPB remains unclear.

During complicated cardiovascular surgery, CPB is used to maintain blood flow and oxygen delivery while diverting blood away from surgical site. It has been reported that this process will lead to platelet activation and a change of cell shape as well as membrane protein presentation.⁶⁶ Importantly, it is reported that GP1b level decreased significantly after surgery.⁵⁰ Additionally, two research showed that GPIIb/IIIa drops significantly soon after CPB and are maintained at low levels 2-4h after the surgery.^{67, 68} The decrease in receptor expression may root from plasmin generated during CPB, which cleaves GPIIb/IIIa.⁶⁹ The acute activation of platelet may also lead to platelet exhaustion which can lead to a defective platelet aggregation.⁷⁰ Another potential mechanism for platelet dysfunction and decreased platelet contractility involves the activation of VWF during CPB. In disease models such as acquired von-Willebrand syndrome, it has been shown that platelet GPIIb/IIIa is inhibited following changes in VWF.^{71, 72} The change in GP1b and GPIIb/IIIa are likely a main factor in altered mechanical force generation of platelets as they are the main mechanosensing and mechanotransduction hub of platelets. During hemostasis, platelets will interact with adhesive ligands such as VWF through GP1b, anchoring the platelets to the injured site.⁷³ Then, platelet aggregation is facilitated by the binding of surface integrin $\alpha_{IIb}\beta_3$ to fibrin and fibrinogen, collagen, fibronectin.⁷⁴ The contractility of the receptors to their surroundings contribute to the strength of the platelet plug and may help reapproximate damaged vascular endothelium.⁷⁵

Current gold standard diagnostic methods for potential bleeding such as TEG measures the viscoelastic properties of clots, which is fundamentally linked to platelet force and the contraction against each other. Other methods that use micropatterned polymer structures to measure the platelet traction force has been used to demonstrate that platelet traction force is correlated to bleeding such as trauma induced coagulopathy,¹⁷ genetic bleeding disorder such as May Hegglin disorder and Wiskott Aldrich Syndrome,¹⁶ and Immune Thrombocytopenia Purpura.⁷⁶ These studies further validate the importance of measuring force in different bleeding pathological settings.

One potential clinical use of MCATS may be in predicting severe bleeding. The universal definition for perioperative bleeding in adult cardiac surgery stratifies patients into five classes, where class 1 and 2 are defined as insignificant, and mild bleeding, while class 3, 4, and 5 indicate moderate, severe, and massive bleeding, respectively.⁷⁷ The definition is based on a number of factors including blood loss and allogeneic blood product transfusion. We followed this definition and classified CPB patients based on clinical observations. We found that patients with moderate, severe, or massive bleeding (class 3, 4, 5) showed a more significant drop in MCATS score compared to patients with mild or insignificant bleeding (**Extended data fig 9**). Because MCATS exclusively quantifies platelet function, more studies are needed for understanding the correlation between platelet function and bleeding risk.

Another unique merit of MCATS is that it measures the aggregate number of mechanical events with $F > T_{tol}$ directly using a conventional plate reader. As a result, MCATS only requires $\sim 5 \mu\text{L}$ of blood or less, and hence a typical blood draw ($\sim 5 \text{ mL}$) is enough to run 1000 assays. Antiplatelet therapies are commonly prescribed to prevent acute arterial thrombosis. However, antiplatelet therapy assessment based on aggregometry has not shown improved outcomes and better benefit/risk for cardiovascular patient.⁷⁸ MCATS can generate personalized dose-response curves for specific drugs rapidly to optimize treatment in a dynamic manner, which may increase the sensitivity and specificity required to guide personalized platelet therapy. So far, we measured the forces applied by GPIIb/IIIa which mediates platelet adhesion and aggregation to assess platelet functions. Other platelet forces mediated by GPIb-IX-V and GPVI can potentially be investigated by attaching different ligands/proteins on DNA tension probe to understand the platelet forces with different receptors under shear flow or in different hemostasis states.⁷⁹ It is also worth noting that live and active cells are required to perform MCATS, and we confirmed that lyophilized platelets (fixed platelets with intact protein structure) failed to generate MCATS signal (**Extended data fig 10**).

In MCATS experiments, different platelet handling procedures may alter platelet response. Therefore, we tested different platelet purification procedures and the results indicated that MCATS can detect tension signal from purified platelets, platelet rich plasma (PRP) and whole blood samples. However, whole blood showed decreased tension signal in MCATS because the high abundance of red blood cells blocked access

499 to the chip surface. We anticipate that applying mild flow conditions would better allow performing MCATS in
500 whole blood. PRP showed slightly decreased MCATS signal compared to that when using purified platelets.
501 Advantages of using PRP include simplifying blood processing steps and decreasing preparation time to run
502 the assay (**Figure S5**). Other advantages of using PRP include maintaining the physiological drug dose
503 found in the blood which is important for assessing drugs that have short half-life or rapid off-rates.
504 Conversely, the use of purified platelets for MCATS enhanced the signal and provided a more direct
505 evaluation of platelet function without interference from soluble factors. However, MCATS measures the
506 mechanical rupture event from cellular receptors under static conditions while platelets function under
507 conditions of shear flow. Thus, MCATS may not fully capture the mechanical response of platelets *in vivo*.
508 Further optimization of the device under flow may be required for more accurate measurement of platelet
509 response in more physiological conditions. Because the assay is performed on glass surfaces, this exposed
510 platelets to substrates with considerably large stiffness that likely perturbs inherent responses. Additionally,
511 we adopted cRGD in current design for engagement with GPIIb/IIIa, which primarily reports on mechanical
512 force transmission from GPIIb/IIIa. MCATS probes that present VWF may lead more comprehensive analysis
513 of platelet force generation. Additionally, other parameters such as coagulation factors such as fibrinogen,
514 VWF, and others, as well as platelet count all influence the coagulation cascade. Hence, combining the
515 results of conventional assays (TEG and LTA) that are already used in the clinic with MCATS may help
516 improve characterization of bleeding risk.

517
518 Another important parameter to consider in MCATS is the assay time. We monitored MCATS signal in
519 platelet and fibroblast experiments with different amplification times. The results showed that 30min
520 amplification provides sufficient signal, but signal could be further enhanced at 60 min. Further increasing
521 amplification time did not lead to significantly improved signal to noise ratio (**Figure S9**). These results
522 indicate that MCATS has potential as a point-of-care assay given the 30 min or 60 min response time.

523
524 Because MCATS measures the accumulated number of mechanical events generated by specific receptors,
525 investigating different cell types or different types of receptors requires optimization of the tension sensor to
526 maximize S/N. For example, we tested both 12 pN and 56pN probes for human platelets and fibroblasts and
527 it was shown that 12 pN probes generated greater MCATS signal in these two cell types. Other cell types
528 such as smooth muscle cells and keratinocytes have been reported to generate significantly greater traction
529 forces and hence greater T_{tol} probes would be appropriate for such models.^{8, 80} The force threshold should
530 be chosen carefully for different applications.

531
532 MCATS provides a sensitive and rapid assay that reports on the total number of molecular force events
533 using a conventional plate reader. The assay may provide a useful tool for the scientific community to study
534 mechanobiology broadly. We envision areas that include the screening of how different adhesion ligands,
535 drugs, genes, as well as cell state and metabolites can modulate traction forces in a high throughput
536 manner.

537 **Methods**

538 **Materials**

539
540 Cy3B-NHS ester (PA63101) was purchased from GE Healthcare Life Sciences (Pittsburgh, PA). Atto647N-
541 NHS ester (18373) was purchased from Sigma Aldrich (St. Louis, MO). Cyclo[Arg-Gly-Asp-d-Phe-Lys(PEG-
542 PEG)] (PCI-3696-PI) (cRGD) was acquired from Peptides International (Louisville, KY). Streptavidin (S000-
543 01) was purchased from Rockland-Inc (Pottstown, PA). μ -Slide VI0.4 6-channel slides (80606) and 25 mm x
544 75 mm glass coverslips (10812) were purchased from Ibidi (Verona, WI). ProPlate® Microtiter (204969) were
545 purchased from Grace Bio-Labs (Bend, OR). 200 proof ethanol (100%, #04-355-223) was purchased from
546 Fischer Scientific. (Waltham, MA) N-hydroxyl succinimide-5 kDa PEG-biotin (NHS-PEG-biotin, HE041024-
547 5K) was purchased from Biochempeg (Watertown, MA). 3-Aminopropyl triethoxysilane (APTES, 440140,
548 99% purity) and adenosine 5'-diphosphate (ADP, A2754, 95% purity) were purchased from Sigma-Aldrich.
549 Tris-hydroxypropyltriazolylmethylamine (THPTA) was purchased from Click Chemistry Tools (Scottsdale,
550

551 AZ). Ticagrelor was acquired from Selleck Chemistry (Houston, TX). 7E3 (Abciximab, Lot: GR3422387-2)
552 was purchased from Abcam. Anti-Integrin $\alpha_v\beta_3$ Antibody (clone LM609, MAB1976, Lot#3863390) and Anti-
553 Integrin $\alpha_5\beta_1$ Antibody (clone JBS5, MAB1969-I, Lot#3941858) was purchased from Sigma Aldrich. Apyrase
554 and LbCas12 were purchased from New England Biolabs (Ipswich, MA). All DNA oligonucleotides used in
555 this work are listed in **Table S1** and were custom synthesized by Integrated DNA Technologies (Coralville,
556 IA). crRNA was custom synthesized by Dharmacon Inc. (Lafayette, CO). All other reagents and materials
557 (unless otherwise stated) were purchased from Sigma-Aldrich and used without purification. All buffers were
558 prepared with 18.2 M Ω nanopure water.

559

560 Instruments

561 We used a Nikon Eclipse Ti microscope, operated by Nikon Elements software, and equipped with a 1.49
562 numerical aperture (NA) CFI Apo $\times 100$ objective, perfect focus system, a TIRF laser launch, a Chroma quad
563 cube (ET-405/488/561/640 nm Laser Quad Band) and an RISM (Nikon: 97270) cube for this work. Bulk
564 fluorescence measurements were conducted using a Synergy H1 plate reader (Bio-Tek) using fluorescence
565 filter sets. All ultrapure water was obtained from a Barnstead Nanopure water purifying system (Thermo
566 Fisher) that indicated a resistivity of 18.2 M Ω . Nucleic acid purification was performed using a high-
567 performance liquid chromatography (HPLC, Agilent 1100) equipped with a diode array detector. Microvolume
568 absorbance measurements were obtained using a Nanodrop 2000 UV-Vis Spectrophotometer (Thermo
569 Scientific). Vacufuge Plus (Eppendorf) was used to remove solvent from HPLC purified sample. Electro-
570 spray ionization (ESI) mass spectrometry identification of product was performed with an Exactive™ Plus
571 Orbitrap Mass Spectrometer. MJ Research PTC-200 Thermal Cycler was used to anneal and hybridize
572 DNA. Platelet counts were determined on a Poch-100i hematology analyzer.

573

574 Surface Preparation

575 MCATS surface preparation was adapted from previously published protocols.^{20, 81} Briefly, rectangular glass
576 coverslips (25 x 75 mm, Ibbidi) were rinsed with water and sonicated for 20 minutes in DI water and then this
577 was repeated for another 20 minutes in ethanol. The glass coverslips were then cleaned with piranha
578 solution which was prepared using a 1:3 mixture of 30% H₂O₂ and H₂SO₄.⁸² WARNING: Piranha solution
579 becomes very hot upon mixing, and is highly oxidizing and may explode upon contact with organic solvents.
580 Please handle with care. Slides were then washed 6 times in ultrapure water, followed by 4 successive
581 washes using ethanol. In a separate beaker of ethanol, slides were reacted with 3% v/v APTES at room
582 temperature for 1 h. Coverslips were then washed 6 times with ethanol, baked in an oven for 20 minutes at
583 80 °C. Subsequently, the amine terminal groups were coupled to NHS-PEG-biotin (3% w/v) by placing 200
584 μ L of a freshly prepared 6 mM NHS-PEG-biotin solution in ultrapure water between two slides for 1 hr. Next,
585 slides were washed 3 times with ultrapure water, dried under N₂ gas, and then stored at -30°C for up to 2
586 weeks or longer before use. At the day of imaging, the 5kDa PEG-biotin substrate was adhered to a ProPlate
587 microtiter 96-well plate housing with an adhesive bottom. Wells were then incubated with 50 μ g/ml (830 nM)
588 streptavidin in 1 x PBS for 1 hr. Wells were then washed with 1XPBS and incubated with 100 nM DNA probe
589 solutions for 1 hr. Finally, the wells were washed with 1x PBS.

590

591 DNA Hybridization and gRNA/Cas12a binding

592 DNA oligonucleotides were hybridized at 100 nM in a 0.2 mL PCR tube before incubating on the surface.
593 Using a MJ Research PTC-200 thermocycler, DNA was first heated to 90°C and then cooled at a rate of
594 1.3°C per min to 35°C. gRNA and Cas12a were incubated for 10min at 37 °C at 500nM in a 0.2 mL PCR
595 tube just before adding to the surface and stored on ice for maximum preservation of activity.

596

597 Oligo dye/ligand coupling and purification

598 All sequences of DNA strands used in this work are provided in **Table S1**. To generate the dye-labeled
599 bottom strand, 10 nmoles of amine-modified DNA was reacted overnight at 4°C with a 20x excess of Cy3B-
600 NHS or ATTO 647N-NHS dissolved in 10 μ L DMSO. The total volume of the reaction was 100 μ L and this
601 was composed of 1x PBS supplemented with 0.1M NaHCO₃. Then a P2 size exclusion gel was used to
602 remove unreacted dye. The product **1** or **2** (**Fig. S3**) was then purified by reverse phase HPLC using an

Agilent Advanced oligo column (Solvent A: 0.1M TEAA, Solvent B: acetonitrile; starting condition: 90% A + 10 % B, 1%/min gradient B, Flow rate: 0.5 mL/min) (**Fig. S3**).

To generate the cRGD-modified top strand (product **3** in **Fig. S3**), 100 nmoles of c(RGDfK (PEG-PEG)) was reacted with ~ 200 nmoles of NHS-azide in 15 μ L of DMSO overnight at 4°C. Product **3** was then purified via reverse phase HPLC using a Grace Alltech C18 column (solvent A: water + 0.05% TFA, solvent B: acetonitrile + 0.05% TFA; starting condition: 90% A + 10 % B, 1%/min; flow rate: 1 mL/min).

Purified product **3** was ligated to the BHQ₂ top strand via 1,3-dipolar cycloaddition click reaction. Briefly, 5 nmoles of alkyne-modified top strand was reacted with ~70 nanomoles of product **3**. The total reaction volume was 50 μ L, composed of 0.1 M sodium ascorbate and 0.1 mM Cu-THPTA for 2h at RT. The product **4** was then purified with a P2 size exclusion column, and then purified with reverse phase HPLC using an Agilent Advanced oligo column (solvent A: 0.1M TEAA, solvent B: acetonitrile; starting condition: 90% A + 10 % B, 0.5%/min gradient B, flow rate: 0.5 mL/min) (**Fig. S3**).

Concentrations of purified oligonucleotide conjugates were determined by measuring their absorption at λ =260 nm on a Nanodrop 2000 UV-Vis Spectrophotometer (Thermo Scientific). ESI- mass spectrometry was performed to validate all oligonucleotide products, and the results are listed in **Table S2**.

Solution based Cas12a amplification and plate reader readout

Cas12a reactions reported in **Figure 1e** were performed at 37°C for 1h in 1 x PBS supplemented with 10 mM MgCl₂. For these measurements, we maintained a total DNA (60 T bottom strand, **Table S1**) solution concentration of 100 nM but tuned the ratio between the blocked DNA and unblocked activator. We prepared freshly primed Cas12a by mixing with gRNA at 1:1 ratio. The primed Cas12a-gRNA complex was then mixed at 20 nM concentration with 100 nM fluorogenic reporter to the well. Then we measured the final fluorescence intensity using a plate reader using a filter set (Ex/Em = 540/590 nm for reporter channel) after allowing the reaction to proceed for 1h.

Human platelet handling and ethics agreement

Blood was collected at Emory Hospital from consented patients/volunteers. For patients, blood was collected from arterial line into 5ml 3.2% citrate tubes (9:1 v/v) at baseline and after CPB (after protamine treatment). For healthy volunteers, blood was collected by venipuncture into citrate tubes as above. Complete blood count (CBC) was performed using Poch-100i hematology analyzer (Sysmex Corp, Kobe, Japan) to evaluate platelet count (PLT). The sample was then centrifuged for 12 min at 140 g (with 0.02U Apyrase). Then PRP was separated and centrifuged for 5 min at 700 g with 3 μ M PGE-1. The platelets were then resuspended in Tyrodes buffer with 3 μ M PGE-1 and centrifuged for 5 min at 700 g. Finally, platelets were resuspended in Tyrodes buffer. It is worth noting that apyrase is important for the platelet purification procedure to prevent hemolysis-triggered platelet aggregation.

Ethics: This project has approval from the Emory University Ethics Committee to obtain samples from participants and these ethical regulations cover the work in this study. Written informed consent was obtained from all participants.

Cell culture

NIH/3T3 fibroblasts and HeLa cells were cultured according to ATCC guidelines. Briefly, cells were cultured in DMEM supplemented with 10% bovine calf serum (v/v, purchased from Gibco) and penicillin/streptomycin. Cells were passaged every 2-3 days as required.

Mechano-Cas12a assisted tension sensor

MCATS was performed on activated substrates as described in the surface preparation section. First, cRGDfK-labelled concealed activator probes were incubated on biotin surfaces in 1x PBS buffer for 1h. The

wells were washed with 1x PBS. Then, cells were added and allowed to spread on the surfaces for 1h in specific media (DMEM supplemented with 1% serum for NIH/3T3 cells and Tyrodes buffer with 10 μ M ADP for platelets). Surfaces were imaged at approximately 1 hr after seeding using epifluorescence and TIRF microscopy to visualize and quantify mechanically exposed activators. Wells were then supplemented with 10 mM $MgCl_2$ and subsequently, 20 nM gRNA/Cas12a complex and 100 nM reporter DNA were mixed and added to the well to initiate the Cas12a amplification reaction with mechanically exposed activator. After 1h of triggering the Cas12a reaction, fluorescence intensities of wells were measured with a Bio-Tek® Synergy H1 plate reader (Ex/Em = 540/590 nm for reporter channel). Note that we always included positive and negative control wells to help benchmark the MCATS signal. The positive control wells were comprised of 100% surface tethered activator oligonucleotides while the negative control was the blocked activator.

Dose-dependent inhibition of receptor mediated tension

For dose-dependent inhibition of fibroblast experiments, the cell density of 3T3 fibroblast was first characterized with a hemocytometer. 25×10^3 cells were incubated with different concentrations of inhibitor in the cell culture incubator for 30 min before plating onto 96 well plates. Afterwards, cells were incubated for 1h to promote cell adhesion. Then the MCATS protocol was followed to achieve amplification and quantification.

For platelet MCATS measurements, human platelets were purified and stored at room temperature for at least 30 min before running experiments. For the drug treatment measurements, platelets were treated with each drug for 30 min before seeding onto 96 well-plates. 10 μ M ADP was added to the well to promote cell activation and adhesion. Then platelets were incubated at room temperature for 1h. The same MCATS protocols that were used for fibroblasts were also followed to achieve amplification and quantification of force generation by platelets.

For HeLa cells integrin subtypes inhibition experiments, the cell density of Hela cells was first characterized with a hemocytometer. 20×10^3 cells were incubated with 10 μ g/ml monoclonal antibody of integrin $\alpha_5\beta_1$ or $\alpha_v\beta_3$ for 30min before running MCATS assays.

Microscopy imaging

For MCATS experiments, Images were acquired on a Nikon Eclipse Ti microscope, operated by Nikon Elements software, a 1.49 NA CFI Apo 100x objective, perfect focus system, and a total internal reflection fluorescence (TIRF) laser launch with 488 nm (10 mW), 561 nm (50 mW), and 638 nm (20 mW). A reflection interference contrast microscopy (RICM) (Nikon: 97270) cube and a Chroma quad cube (ET-405/488/561/640 nm Laser Quad Band) were used for imaging. Images were analyzed using ImageJ. Imaging was performed on 96 well plates and glass coverslips using DMEM as cell imaging media for 3T3 cells and Tyrode's buffer for platelets. All imaging data was acquired at room temperature.

Thromboelastography

TEG measurements were obtained in the operating room using the TEG 6S system (Haemonetics, Braintree, MA) according to manufacturer instructions. This is a fully-automated point of care system shown to have excellent agreement with the TEG 5000 (Haemonetics, Braintree, MA), which has been widely used in cardiac surgery for purposes of guiding hemostatic blood product transfusions.⁸³ Briefly, 2.7 ml of whole blood was collected from the subject's preexisting arterial line into 3.2% citrated tubes. Following the recommended wait time of 10 minutes, approximately 400 μ l of whole blood was pipetted into the sample port of a global hemostasis cartridge (Haemonetics, Braintree, MA). The parameter of interest was the maximum amplitude (MA) of the standard kaolin activated channel. The MA reflects the strength of platelet-fibrinogen interactions.

Light Transmission Platelet Aggregometry

To isolate PRP, blood collected from volunteers/patients was centrifuged at room temperature at 100 x g for 12 min in Megafuge 16R (ThermoScientific, Waltham, MA) equipped with swinging bucket rotor. The PRP layer was removed and PLT count was obtained and if necessary adjusted to less than 400,000/ μ l. Next,

707 samples were re-centrifuged at 2000xg for 20 min to obtain platelet poor plasma (PPP). LTA was
708 accomplished using PAP-8E profiler (Biodata Corp, Horsham, PA) prewarmed to 37°C. The blank (0%
709 aggregation) was set with PPP. For the testing, ADP and TRAP-6 were used as platelet activators. The final
710 concentrations used were 20, 10 μ M for ADP and 10 μ M for TRAP. All LTA testing was performed according
711 to manufacturer's directions. % Aggregation (PA), slope (PS), area under the curve (AUC), lag phase (LG),
712 disaggregation (DA), maximum aggregation (MA) and final aggregation (FA) were recorded.

713 714 **Statistics and reproducibility**

715 P-values were determined by two tailed student's t-test using GraphPad Prism8. Correlation analysis is
716 conducted using GraphPad Prism8 to acquire Person's r in figure 4. Mechano-IC₅₀ is calculated by fitting plot
717 to a standard dose-response function: $\text{Signal} = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + ([\text{drug}] / \text{IC}_{50}))$ using GraphPad
718 Prism8. Each MCATS readout is typically replicated with 2 - 4 wells on the same plate for the same
719 condition. For CPB patient tension signal, all data was acquired along with positive and negative control
720 wells to help benchmark signal. The positive control wells were comprised of 100% surface tethered activator
721 oligonucleotides while the negative control was the blocked activator without platelet seeding. MCATS
722 signal for each run was normalized to the positive control wells also conducted in each experiment and then
723 multiplied by the average intensity of the positive wells collected from past positive control runs. This
724 normalization process helped to minimize the influence of variance in enzyme activity (batch to batch
725 variability) along with variability in the surfaces and other sources of experimental noise.

726 727 **Reporting summary**

728 Further information on research design is available in the Nature Research Reporting Summary linked to this
729 article.

730 731 **Data availability**

732 The data supporting the results in this study are available within the paper and its Supplementary
733 Information. Source data are provided with this paper. All raw and analyzed datasets generated during the
734 study are available from the corresponding author on request. De-identified patient data are available from
735 the corresponding author, subject to IRB approval.

736 737 **Acknowledgements**

738 We acknowledge support from NIH 5R01GM131099-04, NSF DMR 1905947. Y.D. is supported by American
739 Heart Association postdoctoral fellowship. We would like to thank the Emory Mass Spectrometry Center and
740 Dr. Fred Strobel and Dr. Hiroaki Ogasawara for ESI-MS measurement to validate oligonucleotides. We thank
741 BioRender.com for part of the figure creation. We thank Dr. Laura Downey and Dr. Cheryl Maier for helpful
742 discussions.



743 744 **Author Contributions**

745 Y.D. and K.S. conceived the project. Y.D. designed experiments, analyzed data, and compiled the figures.
746 F.S. helped with TEG, aggregometry experiments and related discussions. Y.H., W.C., R.L. M.M. helped with
747 platelets purification and related discussion. Y.K. helped design experiments. F.S. and R.S. helped designed
748 clinical studies and obtained related samples. Y.D. and K.S. wrote the manuscript. All authors helped revise
749 the manuscript.


750 751 **Competing Interests**

752 Y.D., Y.K., R.S., K.S. are the inventors of a patent application (U.S. Application No. 63/417,239). The
753 remaining authors declare no competing interests.

Figure Captions



755
 756 **Extended data figure 1. Comparison of surface density as function of linker length.** A) Scheme
 757 showing surface tethered activator sequences with different linker lengths. B) Plot of normalized surface
 758 density as a function of linker length. All biotinylated activators were incubated on streptavidin modified
 759 surfaces for 1hr at 100nM. Surface density was determined using fluorescence microscopy of fluorescently
 760 tagged activators and normalized to the activator density without linker. Error bar represents S.E.M from five
 761 independent surfaces.




Extended data figure 2. Cas12a auto-cleavage of surface-tethered activator. A) Schematic showing the MCATS process. Molecular traction forces mechanically melt the duplex probe and reveal an activator sequence that triggers Cas12a to cleave the linker of immobilized activators. B) Representative RISM, and duplex rupture (red) fluorescence images after platelets were incubated on concealed activator surface. Imaging was initiated after 1 hr after seeding platelets. The images compare the RISM cell spread area and duplex rupture signal before and after Cas12a/gRNA and reporter DNA were added for 1hr. Scale bar = 12 μm. C) Plot of mean fluorescence intensity beneath individual platelet before and after amplification. Center for the error bars is the mean fluorescence intensity under 10 individual platelets. Values are raw levels and were not background subtracted. Error bar represents S.D from 10 individual platelets. The p value is calculated by two-sided student *t* test. $p < 0.0001$. D) Plot of spread area beneath individual platelets determined from RISM before and after amplification. Significance is calculated with two-sided student *t* test, $p = 0.0002$. Error bar represents S.D from 10 individual platelets.


a)



b)



c)



775

776


777

778

779


780

Extended data figure 3: Integrin subtype inhibition assay with MCATS. a) Scheme showing the workflow of how the integrin inhibition assay was performed with MCATS. b) MCATS results of HeLa cell traction forces inhibited by different integrin monoclonal antibodies. Error bars represent standard error of the mean from $n=4$ ($T_{\text{tot}}=12\text{pN}$) and $n=5$ ($T_{\text{tot}}=56\text{pN}$) independent experiments. Significance is calculated by paired two-tailed t-test.





Extended data figure 4: Measuring MCATS signal as a function of platelet number seeded on a surface. A) Plot of MCATS signal as a function of seeded platelet number. Error bar represents SEM from n=3 independent experiments B) Representative of RICM, duplex rupture (red) fluorescence images and bright field images of tension signal when seeding different number of cells on concealed activator surface.

a)




Extended data figure 5: Day-to-day variance of platelet tension test. A) MCATS results of two healthy donors' platelet tension signal from three individual blood draws performed on separate days.

A) **Light Transmission Aggregometry**



Extended data figure 6: LTA data for platelet treated with different ADP agonist concentrations. A) Plot showing LTA signal of primary aggregation for platelets treated with ADP. LTA was accomplished using PAP-8E profiler prewarmed to 37°C. The blank (0% aggregation) was set with PPP. **B)** Representative RICM, duplex rupture fluorescence (red) images for one donor washed platelets that were treated with ADP with concentrations ranging from 0.1 mM to 20 mM. Scale bar = 10 μm. MCATS signal for this data is shown in main figure 3.



797

798

799

800

801


802

803

804


805

Extended data figure 7: MCATS measures dose-response curves for platelet inhibitors. a-d) Plots of [Aspirin], [Eptifibatide], [7E3], [Ticagrelor] vs MCATS signal for different donors. A dose-response titration of six drug concentrations for each drug for individual donors is measured with MCATS and all measurements were performed in duplicate or triplicate. Mechano-IC₅₀ for each donor was calculated by fitting plot to a standard dose-response function: $\text{Signal} = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + ([\text{drug}] / \text{IC}_{50}))$. Solid line represents the fitting and dashed line represents 95% CI. Representative RISM, duplex rupture fluorescence (red) and zoom-in fluorescence images for one donor with drug concentrations ranging from 0 mM to 10 mM. Scale bar = 10 μm .




Extended data figure 8: Sensitivity of aspirin and ticagrelor for patients before and after surgery. (A)

Plots of [Aspirin] vs MCATS signal for patients before and after surgery. Error bars represent SD from three replicate wells. Center of error bar represents average of the three measurements. Mechano-IC₅₀ for each donor was calculated by fitting plot to a standard dose-response function: $\text{Signal} = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + ([\text{drug}] / \text{IC}_{50}))$. The difference of calculated IC₅₀ before and after surgery for two patients is non-significant with two tailed student t test, $P=0.65$. (B) Plots of [Ticagrelor] vs MCATS signal for patient before and after surgery.. Mechano-IC₅₀ was calculated by fitting plot to a standard dose-response function: $\text{Signal} = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + ([\text{drug}] / \text{IC}_{50}))$.



817 **Extended data figure 9: Patient bleeding severity is correlated with platelet mechanical dysfunction.**
818 Plot of reduction in MCATS signal (%) for subjects binned into two groups: mild/insignificant bleeding (class 1
819 and 2) or moderate/severe/massive bleeding (class 3, 4, and 5). Significance is calculated by a two tailed
820 student t-test with P=0.03. Error bars represent S.E.M. from n=3 and 4 patients.



821 **Extended data figure 10: Tension measurement of lyophilized platelets.** A) Representative RICM,
 822 duplex rupture fluorescence (red) images for lyophilized platelets on tension probes. Scale bar represents 12
 823 μm . B) Plot of MCATS signal of lyophilized platelets seeded on concealed DNA tension probes for 1hr. Error
 824 bar represents SD from 3 independent wells. Results indicate lyophilized platelets have no active mechanical
 825 signal.

826

References

- 827 1. Orr, A.W., Helmke, B.P., Blackman, B.R. & Schwartz, M.A. Mechanisms of mechanotransduction.
828 *Dev. Cell* **10**, 11-20 (2006).
- 829 2. Zhang, Y. et al. Platelet integrins exhibit anisotropic mechanosensing and harness piconewton
830 forces to mediate platelet aggregation. *Proc. Natl. Acad. Sci.* **115**, 325-330 (2018).
- 831 3. Ma, R. et al. DNA probes that store mechanical information reveal transient piconewton forces
832 applied by T cells. *Proc. Natl. Acad. Sci.* **116**, 16949-16954 (2019).
- 833 4. Ramey-Ward, A.N., Su, H. & Salaita, K. Mechanical Stimulation of Adhesion Receptors Using Light-
834 Responsive Nanoparticle Actuators Enhances Myogenesis. *ACS Appl. Mater. Interfaces* **12**, 35903-
835 35917 (2020).
- 836 5. Wang, X. & Ha, T. Defining single molecular forces required to activate integrin and notch signaling.
837 *Science* **340**, 991-994 (2013).
- 838 6. Gaudet, C. et al. Influence of type I collagen surface density on fibroblast spreading, motility, and
839 contractility. *Biophys. J.* **85**, 3329-3335 (2003).
- 840 7. Zhang, Y., Ge, C., Zhu, C. & Salaita, K. DNA-based digital tension probes reveal integrin forces
841 during early cell adhesion. *Nat. Commun.* **5**, 5167 (2014).
- 842 8. Rashid, S.A. et al. DNA Tension Probes Show that Cardiomyocyte Maturation Is Sensitive to the
843 Piconewton Traction Forces Transmitted by Integrins. *ACS Nano* **16**, 5335-5348 (2022).
- 844 9. Su, H. et al. Massively Parallelized Molecular Force Manipulation with On-Demand Thermal and
845 Optical Control. *J.A.C.S.* **143**, 19466-19473 (2021).
- 846 10. Doudna, J.A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9.
847 *Science* **346**, 1258096 (2014).
- 848 11. Kaminski, M.M., Abudayyeh, O.O., Gootenberg, J.S., Zhang, F. & Collins, J.J. CRISPR-based
849 diagnostics. *Nat. Biomed. Eng.* **5**, 643-656 (2021).
- 850 12. Chen, J.S. et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase
851 activity. *Science* **360**, 436-439 (2018).
- 852 13. Gootenberg, J.S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a,
853 and Csm6. *Science* **360**, 439-444 (2018).
- 854 14. Broughton, J.P. et al. CRISPR-Cas12-based detection of SARS-CoV-2. *Nat. Biotechnol.* **38**, 870-
855 874 (2020).
- 856 15. Xiong, Y. et al. Functional DNA regulated CRISPR-Cas12a sensors for point-of-care diagnostics of
857 non-nucleic-acid targets. *J. Am. Chem. Soc.* **142**, 207-213 (2019).
- 858 16. Myers, D.R. et al. Single-platelet nanomechanics measured by high-throughput cytometry. *Nat.*
859 *Mater.* **16**, 230-235 (2017).
- 860 17. Ting, L.H. et al. Contractile forces in platelet aggregates under microfluidic shear gradients reflect
861 platelet inhibition and bleeding risk. *Nat. Commun.* **10**, 1-10 (2019).
- 862 18. Cuisset, T. et al. Relationship between aspirin and clopidogrel responses in acute coronary
863 syndrome and clinical predictors of non response. *Thromb. Res.* **123**, 597-603 (2009).
- 864 19. Neira, H.D. & Herr, A.E. Kinetic analysis of enzymes immobilized in porous film arrays. *Anal. Chem.*
865 **89**, 10311-10320 (2017).
- 866 20. Duan, Y. et al. Mechanically Triggered Hybridization Chain Reaction. *Angew. Chem. Int. Ed.* **60**,
867 19974-19981 (2021).
- 868 21. Glazier, R. et al. DNA mechanotechnology reveals that integrin receptors apply pN forces in
869 podosomes on fluid substrates. *Nat. Commun.* **10**, 4507 (2019).
- 870 22. Wang, X. et al. Integrin Molecular Tension within Motile Focal Adhesions. *Biophys. J.* **109**, 2259-
871 2267 (2015).
- 872 23. Sahai, E., Ishizaki, T., Narumiya, S. & Treisman, R. Transformation mediated by RhoA requires
873 activity of ROCK kinases. *Curr. Biol.* **9**, 136-145 (1999).
- 874 24. Oba, M. et al. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery
875 system directed to cells possessing $\alpha v \beta 3$ and $\alpha v \beta 5$ integrins. *Bioconjug. Chem.* **18**, 1415-1423
876 (2007).
- 877 25. Riikonen, T., Vihinen, P., Potila, M., Rettig, W. & Heino, J. Antibody against human $\alpha 1 \beta 1$ integrin
878 inhibits HeLa cell adhesion to laminin and to type I, IV, and V collagens. *Biochem. Biophys. Res.*
879 *Commun.* **209**, 205-212 (1995).
- 880 26. Yamada, Y. et al. Structure-Activity Relationships of RGD-Containing Peptides in Integrin $\alpha v \beta 5$ -
881 Mediated Cell Adhesion. *ACS omega* (2023).

- 882 27. Belkin, A.M. et al. Transglutaminase-mediated oligomerization of the fibrin (ogen) α C domains
883 promotes integrin-dependent cell adhesion and signaling. *Blood* **105**, 3561-3568 (2005).
- 884 28. Roca-Cusachs, P., Gauthier, N.C., Del Rio, A. & Sheetz, M.P. Clustering of α 5 β 1 integrins
885 determines adhesion strength whereas α v β 3 and talin enable mechanotransduction. *Proc. Natl.*
886 *Acad. Sci.* **106**, 16245-16250 (2009).
- 887 29. Galior, K., Liu, Y., Yehl, K., Vivek, S. & Salaita, K. Titin-based nanoparticle tension sensors map
888 high-magnitude integrin forces within focal adhesions. *Nano Lett.* **16**, 341-348 (2016).
- 889 30. Brockman, J.M. et al. Live-cell super-resolved PAINT imaging of piconewton cellular traction forces.
890 *Nat. Methods* **17**, 1018-1024 (2020).
- 891 31. Brockman, J.M. et al. Mapping the 3D orientation of piconewton integrin traction forces. *Nat.*
892 *Methods* **15**, 115-118 (2018).
- 893 32. Hu, Y. et al. DNA-based microparticle tension sensors (μ TS) for measuring cell mechanics in non-
894 planar geometries and for high-throughput quantification. *Angew. Chem. Int. Ed.* **133**, 18192-18198
895 (2021).
- 896 33. Dias, J.D. et al. Comparison of three common whole blood platelet function tests for in vitro P2Y12
897 induced platelet inhibition. *J. Thromb. Thrombolysis* **50**, 135-143 (2020).
- 898 34. Le Blanc, J., Mullier, F., Vayne, C. & Lordkipanidzé, M. Advances in Platelet Function Testing—Light
899 Transmission Aggregometry and Beyond. *J. Clin. Med.* **9**, 2636 (2020).
- 900 35. Davidson, B.L. et al. Bleeding Risk of Patients With Acute Venous Thromboembolism Taking
901 Nonsteroidal Anti-Inflammatory Drugs or Aspirin. *JAMA Intern. Med.* **174**, 947-953 (2014).
- 902 36. Awtry, E.H. & Loscalzo, J. Aspirin. *Circulation* **101**, 1206-1218 (2000).
- 903 37. Phillips, D.R. & Scarborough, R.M. Clinical pharmacology of eptifibatide. *Am. J. Cardiol.* **80**, 11B-20B
904 (1997).
- 905 38. Tcheng, J.E. et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody
906 Fab 7E3 in high-risk coronary angioplasty. *Circulation* **90**, 1757-1764 (1994).
- 907 39. Roth, G. & Majerus, P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of
908 a particulate fraction protein. *J. Clin.* **56**, 624-632 (1975).
- 909 40. Tardiff, B.E. et al. Pharmacodynamics and Pharmacokinetics of Eptifibatide in Patients With Acute
910 Coronary Syndromes. *Circulation* **104**, 399-405 (2001).
- 911 41. Sassoli, P.M. et al. 7E3 F (ab')₂, an effective antagonist of rat α IIb β 3 and α v β 3, blocks in vivo
912 thrombus formation and in vitro angiogenesis. *Thromb. Haemost.* **85**, 896-902 (2001).
- 913 42. Aungraheeta, R. et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade
914 contribute to platelet inhibition by ticagrelor. *Blood* **128**, 2717-2728 (2016).
- 915 43. Wang, X. et al. Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-
916 Induced Platelet Activation and Adhesion. *J. Pharmacol. Exp. Ther.* **303**, 1114-1120 (2002).
- 917 44. Harder, S. et al. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory
918 comparison of various platelet function tests. *Thromb. Res.* **102**, 39-48 (2001).
- 919 45. De La Cruz, J., Bellido, I., Camara, S., Martos, F. & De La Cuesta, F.S. Effects of acetylsalicylic acid
920 on platelet aggregation in male and female whole blood: an in vitro study. *Scand. J. Haematol.* **36**,
921 394-397 (1986).
- 922 46. Kirkby, N. et al. Antiplatelet effects of aspirin vary with level of P2Y (12) receptor blockade supplied
923 by either ticagrelor or prasugrel. *J. Thromb. Haemost.* (2011).
- 924 47. Greiff, G. et al. Prediction of bleeding after cardiac surgery: comparison of model performances: a
925 prospective observational study. *J. Cardiothorac. Vasc. Anesth.* **29**, 311-319 (2015).
- 926 48. Dyke, C. et al. Universal definition of perioperative bleeding in adult cardiac surgery. *J. Thorac.*
927 *Cardiovasc. Surg.* **147**, 1458-1463. e1451 (2014).
- 928 49. Bartoszek, J. et al. Comparison of Two Major Perioperative Bleeding Scores for Cardiac Surgery
929 Trials: Universal Definition of Perioperative Bleeding in Cardiac Surgery and European Coronary
930 Artery Bypass Grafting Bleeding Severity Grade. *Anesthesiology* **129**, 1092-1100 (2018).
- 931 50. Kondo, C. et al. Platelet dysfunction during cardiopulmonary bypass surgery. With special reference
932 to platelet membrane glycoproteins. *Asaio. j.* **39**, M550-553 (1993).
- 933 51. Roka-Moiia, Y. et al. Platelet Dysfunction During Mechanical Circulatory Support. *Arterioscler.*
934 *Thromb. Vasc. Biol.* **41**, 1319-1336 (2021).
- 935 52. Bartoszek, J., Wijesundera, D.N. & Karkouti, K. Comparison of two major perioperative bleeding
936 scores for cardiac surgery trials: universal definition of perioperative bleeding in cardiac surgery and
937 European coronary artery bypass grafting bleeding severity grade. *Anesthesiology* **129**, 1092-1100
938 (2018).
- 939 53. Ranucci, M. et al. Platelet function after cardiac surgery and its association with severe
940 postoperative bleeding: the PLATFORM study. *Platelets* **30**, 908-914 (2019).
- 941 54. Welsh, K.J., Padilla, A., Dasgupta, A., Nguyen, A.N.D. & Wahed, A. Thromboelastography Is a
942 Suboptimal Test for Determination of the Underlying Cause of Bleeding Associated With
943 Cardiopulmonary Bypass and May Not Predict a Hypercoagulable State. *Am. J. Pathol.* **142**, 492-
944 497 (2014).

- 945 55. Welsby, I.J. et al. The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. *J*
946 *Cardiothorac Vasc Anesth* **20**, 531-535 (2006).
- 947 56. Bowbrick, V.A., Mikhailidis, D.P. & Stansby, G. Influence of platelet count and activity on
948 thromboelastography parameters. *Platelets* **14**, 219-224 (2003).
- 949 57. Choi, J.-L., Li, S. & Han, J.-Y. Platelet Function Tests: A Review of Progresses in Clinical
950 Application. *BioMed Res. Int.* **2014**, 456569 (2014).
- 951 58. Kaufmann, C.R., Dwyer, K.M., Crews, J.D., Dols, S.J. & Trask, A.L. Usefulness of
952 thrombelastography in assessment of trauma patient coagulation. *J. Trauma.* **42**, 716-720;
953 discussion 720-712 (1997).
- 954 59. Moenen, F.C. et al. Screening for platelet function disorders with Multiplate and platelet function
955 analyzer. *Platelets* **30**, 81-87 (2019).
- 956 60. Quarterman, C., Shaw, M., Johnson, I. & Agarwal, S. Intra- and inter-centre standardisation of
957 thromboelastography (TEG®). *Anaesthesia* **69**, 883-890 (2014).
- 958 61. Harr, J.N. et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal
959 clot strength following trauma. *Shock* **39**, 45-49 (2013).
- 960 62. Slichter, S.J. et al. Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage. *N.*
961 *Engl. J. Med.* **362**, 600-613 (2010).
- 962 63. Femia, E.A., Scavone, M., Lecchi, A. & Cattaneo, M. Effect of platelet count on platelet aggregation
963 measured by impedance aggregometry (Multiplate (™) analyser) and by light transmission
964 aggregometry. *J. Thromb. Haemost.* **11**, 2193-2196 (2013).
- 965 64. Boknäs, N., Macwan, A.S., Södergren, A.L. & Ramström, S. Platelet function testing at low platelet
966 counts: When can you trust your analysis? *Res. Pract. Thromb. Haemost.* **3**, 285-290 (2019).
- 967 65. Greilich, P.E., Carr, M.E., Jr., Carr, S.L. & Chang, A.S. Reductions in platelet force development by
968 cardiopulmonary bypass are associated with hemorrhage. *Anesth. Analg.* **80**, 459-465 (1995).
- 969 66. Zwifelhofer, N.M.J. et al. Platelet Function Changes during Neonatal Cardiopulmonary Bypass
970 Surgery: Mechanistic Basis and Lack of Correlation with Excessive Bleeding. *Thromb. Haemost.*
971 **120**, 94-106 (2020).
- 972 67. Holada, K., Šimák, J., Kučera, V., Rožňová, L. & Eckschlager, T. Platelet membrane receptors
973 during short cardiopulmonary bypass - a flow cytometric study. *Perfusion* **11**, 401-406 (1996).
- 974 68. Rinder, Christine S. et al. Modulation of Platelet Surface Adhesion Receptors during
975 Cardiopulmonary Bypass. *Anesthesiology* **75**, 563-570 (1991).
- 976 69. Gouin, I. et al. In vitro effect of plasmin on human platelet function in plasma. Inhibition of
977 aggregation caused by fibrinogenolysis. *Circulation* **85**, 935-941 (1992).
- 978 70. Pareti, F.I., Capitanio, A., Mannucci, L., Ponticelli, C. & Mannucci, P.M. Acquired dysfunction due to
979 the circulation of "exhausted" platelets. *Am. J. Med.* **69**, 235-240 (1980).
- 980 71. Guerrero, J.A. et al. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type
981 von Willebrand disease mutation. *Blood* **114**, 5541-5546 (2009).
- 982 72. Casari, C. et al. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin
983 αIIbβ3. *J. Clin. Invest.* **123**, 5071-5081 (2013).
- 984 73. Andrews, R.K., López, J. & Berndt, M.C. Molecular mechanisms of platelet adhesion and activation.
985 *Int. J. Biochem. Cell Biol.* **29**, 91-105 (1997).
- 986 74. Chen, Y. et al. An integrin αIIbβ3 intermediate affinity state mediates biomechanical platelet
987 aggregation. *Nat. Mater.* **18**, 760-769 (2019).
- 988 75. Daniel, J. & Tuszynski, G. Platelet contractile proteins. *Hemostasis and thrombosis: basic principles*
989 *and clinical practice. Philadelphia: JB Lippincott*, 569-573 (1994).
- 990 76. Oshinowo, O.T., Copeland, R., Bennett, C.M., Lam, W.A. & Myers, D.R. Platelet Contraction Force
991 As a Biophysical Biomarker for Bleeding Risk in Patients with Immune Thrombocytopenia. *Blood*
992 **132**, 517-517 (2018).
- 993 77. Dyke, C. et al. Universal definition of perioperative bleeding in adult cardiac surgery. *J. Thorac.*
994 *Cardiovasc. Surg.* **147**, 1458-1463.e1451 (2014).
- 995 78. Wang, T.Y. et al. Cluster-randomized clinical trial examining the impact of platelet function testing on
996 practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of
997 treatment patterns and events after acute coronary syndrome prospective open label antiplatelet
998 therapy study. *Circ. Cardiovasc. Interv.* **8**, e001712 (2015).
- 999 79. Feghhi, S. et al. Glycoprotein Ib-IX-V Complex Transmits Cytoskeletal Forces That Enhance Platelet
1000 Adhesion. *Biophys. J.* **111**, 601-608 (2016).
- 1001 80. Lee, J., Leonard, M., Oliver, T., Ishihara, A. & Jacobson, K. Traction forces generated by locomoting
1002 keratocytes. *J. Cell Biol.* **127**, 1957-1964 (1994).
- 1003 81. Liu, Y. et al. DNA-based nanoparticle tension sensors reveal that T-cell receptors transmit defined
1004 pN forces to their antigens for enhanced fidelity. *Proc. Natl. Acad. Sci.* **113**, 5610-5615 (2016).
- 1005 82. Au - Ma, R. et al. DNA Tension Probes to Map the Transient Piconewton Receptor Forces by
1006 Immune Cells. *J. Vis. Exp.*, e62348 (2021).

- 1007 83. Gurbel, P.A. et al. First report of the point-of-care TEG: a technical validation study of the TEG-6S
1008 system. *Platelets* **27**, 642-649 (2016).